

Appetite Stimulants in Long Term Care: A Literature Review

D Rudolph

Citation

D Rudolph. *Appetite Stimulants in Long Term Care: A Literature Review*. The Internet Journal of Advanced Nursing Practice. 2009 Volume 11 Number 1.

Abstract

Weight loss and malnutrition present a significant challenge to providers in the long term care arena who frequently must evaluate and treat residents for these issues. Reasons for the incidence of unintentional weight loss includes multiple comorbid conditions, polypharmacy, depression and the cachexia of aging. The purpose of this review was to identify current research related to the use of appetite stimulants in long term care. Methods: a review of the literature was conducted from 1956 to present with a focus on long term care, appetite stimulants and weight loss. Results: Traditional approaches to address this issue have included comprehensive nutritional assessment, oral supplements and the use of appetite stimulants. These have included medications such as mirtazepine, oxandrolone, dronabinol, and megestrol acetate. Of these medications, megestrol acetate has been the most widely studied but with mixed results. Providers are encouraged to provide a comprehensive approach to the management of unintentional weight loss in nursing home residents and to consider an appetite stimulant as a last resort, if at all.

BACKGROUND

Unintentional weight loss (UIWL) is a common problem in the long term care (LTC) population. UIWL is often defined as a loss of 5% of the actual body weight in one month or 10% in a six month period [1]. Weight loss is associated with a number of complications including anemia, immune deficiency, postoperative complications, a decline in activities of daily living, pressure ulcers, falls, fractures, and increased mortality [2]. Weight loss and malnutrition in the elderly represent a major concern among health care providers as those aged 80 and older are currently the fastest growing segment of the nation's population. The incidence of involuntary weight loss among nursing home residents is high and ranges from 30-50% in a population of more than 1.7 million residents [3].

In the long term care setting, unintentional weight loss is thought to be multifactorial. Most older adults have at least one chronic disease such as cardiovascular disease, diabetes, hypertension, or renal insufficiency. As a result, they often have a restricted diet which can lead to decrease oral intake. Depression, a highly prevalent condition in this group, also leads to a decrease in food intake [4]. Polypharmacy is another important cause of unintentional weight loss. Medications such as angiotensin converting enzyme (ACE) inhibitors, quinolones, and metronidazole, for example, can

cause dysgeusia leading to decreased appetite.

Cholinesterase inhibitors and selective serotonin reuptake inhibitors can cause nausea, vomiting and diarrhea.

Antidepressants and psychotropics can lead to sedation and decreased attentiveness during mealtimes. Consequently, such medications can lead to decreased food intake [5].

Other causes of weight loss in the elderly include difficulty with chewing due to dental problems, swallowing disorders, cognitive impairment, loss of taste and sensation, and difficulty with self feeding [6, 7].

Regulation of food intake changes with increasing age, leading to what has been described as the "physiologic anorexia of aging" The amount of circulating cholecystokinin, a satiety hormone, increases in the circulation [8]. Leptin, a peptide hormone produced in adipose tissue may also play a role in long term satiety and hunger drive, although the relevance of peptide hormones in older adults remains unclear [9, 10].

The role of elevated cytokines, including tumor necrosis factor (TNF) and interleukin 6 (IL-6) have also been implicated in this syndrome. In the geriatric populations, anorexia and cachexia leading to diminished host defenses are often unexplained. One possible etiology is an association with elevated cytokine levels such as tumor

necrosis factor (TNF), Interleukin-6 (IL-6), and soluble Interleukin-2 receptor (sIL-2) which have been noted in cancer, HIV, and more recently in geriatric wasting syndrome. Production of these cytokines therefore may be involved in unintentional weight loss in older adults and specifically in long term care residents. [11].

Evaluation and treatment of unintentional weight loss in the older adult in long term care settings involves a comprehensive approach. Evaluation includes screening, assessment and treatment. Specific treatments may include the use of nutritional supplementation, and pharmacological approaches. Identification and management of the underlying cause(s) of weight loss is the goal of care. In some cases, however, oral supplements and appetite stimulants have been used in an effort to reverse the process. The goal of this paper is to review the specific role of appetite stimulants in the long term care setting for unintentional weight loss.

METHODOLOGY

A comprehensive literature review of Pub Med, Medline (1956-present), and Scopus was performed. Search terms included unintentional weight loss, long term care, nursing home, appetite stimulants, orexigenics, megesterol acetate, dronabinol, mirtazepine, cyproheptadine, and oxandrolone. A total of 128 articles were retrieved. Any studies or reviews dealing with the use of appetite stimulants specifically in HIV, cancer, or AIDs populations were excluded. Literature reviews, randomized control trials, non randomized trials, case control studies and clinical practice guidelines were included. A total of 21 articles were retained for review.

RESULTS

Numerous pharmacologic agents have been used as appetite stimulants to treat unintentional weight loss in the long term care setting. These agents include mirtazepine, cyproheptadine, oxandrolone, dronabinol, and megesterol acetate. Interestingly, a paucity of evidence is available on most of these agents used in this setting. Many agents have been used based on anecdotal evidence or in off label applications. What appears in the literature to date on these agents is limited. The following represents what is known to date on the use of appetite stimulants in the long term care population

MIRTAZEPINE (REMERON)

Mirtazepine is a serotonergic norepineprine uptake inhibitor that has been used in the treatment of depression. As such,

mirtazepine has demonstrated efficacy in treating depression among older adults in the long term care setting [12]. In one study using mirtazepine to treat late life depression, there was an increase in weight of 1.1 pounds in 4 weeks and 1.32 pounds in 12 weeks, however, the outcome was not found to be statistically significant [13]. In other studies comparing mirtazepine with other antidepressants for the treatment of depression, no significant changes in weight were reported [14, 15]. Morley[16] suggested that mirtazepine is the drug of choice in treating older adults with both depression and weight loss. Although commonly used for the purposes of promoting weight gain, no studies exist to date that have specifically explored the use of mirtazepine as an appetite stimulant in the long term care setting.

CYPROHEPTADINE (PERIACTIN)

Cyproheptadine is an antihistamine that has been used as an appetite stimulant in nursing home residents. This medication has a number of anticholinergic effects that may cause symptoms such as blurred vision, dry mouth, urinary retention constipation, tachycardia and delirium in older patients. These effects generally limit its utility in long term care. Although cyproheptadine has anecdotally been used in this setting, no studies have been undertaken to date using cyproheptadine as an Orexigenic in this population. Much of the data regarding its benefit as such comes from studies involving the pediatric population. Cyproheptadine has also been studied in the treatment of weight loss in both cancer and anorexia nervosa [17].

OXANDROLONE (OXANDRIN)

Oxandrolone is a synthetic anabolic steroid that helps to restore lean muscle mass and increase visceral protein stores. Oxandrolone is the only anabolic steroid approved by the Federal Drug Administration (FDA) for the treatment of cachexia. Oxandrolone has also been found to demonstrate a significant improvement in wound healing over a 12 week period in eight out of eight patients with weight loss and non healing chronic wounds [18]. In another study by Yeh et al. [19], oxandrolone was found improve appetite and increase weight gain in patients with COPD associated weight loss. No studies to date were found that specifically address the use of this agent in the nursing home population. Oxandrolone is contraindicated for use in patients with prostate or breast cancer and may lead to hirsutism and fluid retention. Oxandrolone should also be used with caution in patients with hepatic disease [4].

DRONABINOL (MARINOL)

Dronabinol is a synthetic form of tetrahydrocannabinol, an active ingredient of cannabis or marijuana. Dronabinol has been found to have both antiemetic and appetite stimulant properties. Dronabinol may improve mood and decrease pain as well, making this agent an efficacious option in managing end of life symptoms. The mechanism of action is not well understood. Anorexia and progressive weight loss are often observed in patients with advanced stages of cancer and HIV infection. Dronabinol in several studies was found to convey some benefit to these populations [20, 21]. Dronabinol has only been studied to limited extent in older adults. In a placebo controlled crossover design, dronabinol was studied over a 6 week period in 15 patients with Alzheimer's disease who displayed food refusal [22]. A minimal but statistically significant improvement in weight gain (1.5 pounds) was noted as compared to placebo. No difference in caloric intake was noted between the control and treatment group. During dronabinol treatment disturbed behavior decreased and was attributed to the weight gain exhibited, possibly due to a decrease in overall activity levels. The study was unclear in terms of whether weight gain resulted from decreased energy expenditure or from the treatment itself. In a retrospective observational pilot study [23], 28 subjects with anorexia and significant weight loss were treated with dronabinol over a 12 week period. Fifteen subjects, or 53.5%, gained weight on dronabinol with a mean gain of 3 +/- 8.01 pounds, however, such weight gain was not found to be statistically significant. Eleven subjects lost weight on dronabinol and were younger in age than those who gained weight (70.9 years versus 90.8 years) and the outcome was statistically significant. The authors in this study surmised that failure to respond to dronabinol may indicate increased risk of death; however, no statistical tests to explore this particular hypothesis were conducted.

MEGESTEROL ACETATE (MEGACE)

Megesterol acetate (MA) is a progestational agent with a strong impact on appetite. MA was originally used as a contraceptive agent; however, its side effect of weight gain led to its use as an orixigenic agent. MA is currently FDA approved for the treatment of HIV associated weight loss and is also used to suppress estrogen levels in women with breast and endometrial cancer [24]. MA is associated with side effects such as fluid retention, nausea, glucose intolerance, venous thrombosis and adrenal insufficiency with chronic usage [4]. MA has also been associated with the development of osteoporosis in some patients [25].

In the long term care population, MA has been widely used as an appetite stimulant. In terms of studies that specifically address the use of this agent in this population, a total of 9 studies were found with mixed outcomes. In a pilot study by Castle et al. [26], four patients with a history of weight loss greater than or equal to their ideal body weight with a mean age of 87.5 years were treated with a dose of 400 mg daily for a period of six weeks. Only one of the four completed the study due to reports of confusion, early mental status changes or not "feeling right". Of the four subjects, one gained 6.4 kg and one gained 1.8 kg. This study was too small to draw any significant conclusions and lasted only 6 weeks. In this study, confusion among the residents appeared to be a major side effect. Such side effects are clearly a concern in this frail population. Potentially these side effects might be ameliorated in a future study with a smaller dose; however, an adjustment in dosing may also affect the efficacy of treatment and needs to be further explored.

In a retrospective chart review by Karcic et al. [27], the authors identified 13 residents in two long term care facilities who were treated with MA for malnutrition. The usual dose was 800 mg daily but varied from 200 to 800 mg. The residents had a variety of conditions which included depression, dementia, and terminal neoplasms. Parameters such as food intake, body mass index (BMI), albumin, prealbumin, hemoglobin, white blood cell count and absolute lymphocyte count were assessed over six month period. With MA treatment, all of the nutritional parameters improved ($P < 0.05$). In this study, MA was discontinued in one patient due to an episode of heart failure. The authors concluded that MA is a safe and efficient means of improving malnutrition in nursing home residents. What has not been established in this study is what other confounding factors play into these results and if the improvement in nutritional parameters is related to other interventions or supplements that were not noted by the authors. Another issue which has not been addressed is the long term effects of MA treatment and whether a correlation exists between increased nutritional parameters and long term survival.

In an effort to explore the interrelationship between baseline nutritional status, changes in nutritional status over time and the incidence of adverse outcomes, Sullivan et al. [28] underwent a prospective observational study of nutritionally at risk nursing home residents. This study is referred to as the GAIN Registry (Geriatric Anorexia Nutrition). In this case, the investigators looked at many of the same parameters as Karcic et al. [27]; however, their sample size

was considerably larger with 1000 participants from 96 facilities. Of these, a final sample of 894 was evaluated over a 6 month period. The inclusion criteria for nutritional risk were clearly defined. Outcome measures included appetite improvement, weight gain, and mortality. Specifically, the authors hypothesized that patients who experienced weight loss during this period would have a higher rate of mortality compared to those who did not. Sullivan et al. [28] reported that younger age was the strongest correlate of appetite improvement. The odds of gaining weight were negatively correlated with body mass index (BMI), age and feeding dependency. A weight loss during this period was associated with a two fold increase in the likelihood of dying (adjusted RR; 1.95, 95% CI 1.43-2.66). Interestingly, residents who received appetite stimulants (12% of the sample) were 70% more likely to gain weight. Unfortunately, the authors did not address each stimulant separately. Consequently drawing more definitive conclusions about the efficacy of using orixigenics in general is difficult. Determining which specific agents are most likely to produce more optimal outcomes also presents a challenge.

Yeh et al. [11] conducted a prospective, double blind, placebo controlled trial. These investigators evaluated 69 nursing home residents with a weight loss of > 5% over the past 3 months or body weight 20% less than their ideal weight. Patients were randomly assigned to receive either placebo or MA 800mg daily for 12 weeks with a subsequent follow up period of 13 weeks. The authors published a series of reports on their findings. In their initial study [29] data were collected on appetite, weight, nutritional status, quality of life (QOL), and cytokine levels at baseline and at week 12. Appetite, sense of well being, and QOL were significantly improved in the MA arm. A negative correlation between prealbumin levels and cytokine levels was noted. Improvement in appetite, correlated positively with improvement in nutritional parameters, and weight. Although promising, the study is limited by the fact that the majority of the patients in the sample was male and may not be predictive of the effect on females. Further study of the safety of long term usage is warranted.

In a follow up report by Yeh et al. [11], the authors used results from the same study to evaluate the effects of MA versus placebo on weight. In this instance, the primary outcome was measured by weight and appetite change. At 12 weeks, (the end of the study), no significant difference in weight gain was observed between treatment groups, however at 25 weeks, 61.8% of the MA treated group gained

weight (1.82 kg) compared with 21.7% of the placebo patients. Statistically this weight gain was significant at $p=0.13$, suggesting that a minimum of 3 months of treatment or longer is required to realize a significant difference.

In a subsequent analysis on this same sample, Yeh et al. [30] explored the correlation between cytokine levels and body weight. The hypothesis was based on findings in lab animals in which a reduction of proinflammatory cytokines was noted in animals exhibiting weight gain. In this study, a decrease in cytokine levels in both the placebo group and the MA treated group was observed; however, no significant difference was identified between the groups. In the MA treated group, a negative correlation was noted between cytokine levels and weight, fat mass, and fat free mass (FFM) which was significant at $P<0.05$.

Yeh et al [31] in a later report evaluated cytokine levels and nutritional markers such as prealbumin, white cell counts, and C reactive protein at baseline and after 12 weeks of therapy on survival rates. No significant difference in survival between the placebo and MA treated groups was observed. In terms of confounding factors, it was not clear as to whether elevated cytokines were independent variables leading to decreased survival or a result of an underlying chronic health condition. This area clearly is in need of further study. The cumulative reports by Yeh and colleagues raise some interesting clinical questions and underscore the need for future studies with larger sample sizes and control of possible confounding factors such as underlying conditions [11,29,30,31].

Interest in treating weight loss in the nursing home population prompted Simmons et al. [32] to conduct a nonrandomized clinical trial to assess the effect of megesterol acetate on oral food and fluid intake. In this pilot study, 36 participants were recruited from a larger study and treated with a daily dose of 400 mg of megesterol acetate daily for 63 days. The MA was administered under two conditions: usual nursing home care and when optimal feeding assistance was provided during meals. Of the 36 participants, only 17 completed the study. MA had a significant effect on oral food and fluid intake but only under optimal feeding conditions. No change was made in food or fluid intake under the usual nursing home conditions. Limitations of this study include a very small sample size, a high rate of attrition, and lack of a control group receiving optimal feeding assistance alone. The results of this study suggest that optimal feeding conditions may play a greater role on food and fluid intake than the use of MA. Consequently, the

question of whether optimizing feeding is more effective than the use of orexigenics in LTC is raised and clearly warrants further investigation.

In an effort to examine the effects of megestrol acetate on weight and overall mortality, Bodenner et al. [33] conducted a case control cohort study of 17,33238 nursing home residents admitted to a nursing home system over a three year period with a history of a 5% weight loss over 3 months or 10% over 6 months. Seven hundred nine MA treated patients were matched with 1418 non MA treated patients. The median survival of MA treated patients (23.9 months, 95% CI 20.2-27.5) was significantly less than non MA treated patients (31.2 months, 95% CI 27.8-35.9) ($P < 0.001$). Median weight differences after 6 months were unchanged. MA treatment of elderly nursing home residents according to the findings of this study was associated with an increase in all cause mortality without a significant increase in weight. This study is compelling and again underscores the need for randomized prospective studies with adequate sample sizes are needed to more fully understand the efficacy (or lack thereof), morbidity, and mortality associated with this treatment.

CONCLUSIONS AND IMPLICATIONS FOR PRACTICE

The evidence available to date regarding the use of orexigenics in long term care is substantially lacking with no evidence to support the use of cyproheptadine , oxandolone, or mirtazepine as an appetite stimulant for treating unintentional weight loss in long term care residents. Limited evidence that suggests that dronabinol may be of benefit in this population and some evidence that suggests that megestrol acetate may be of benefit; however, its use is not without risks and has not been studied for long term periods of time (>6 months). (See Table 1)

Of the nine studies identified that specifically addressed the issue of megestrol acetate in long term care, most were limited by small sample sizes and short treatment duration [11, 26, 27, 28,29, 32]. Confounding factors were difficult to identify, and in the case of the work of Yeh et al. [11, 29, 30,31], the sample of 69 mostly male residents was not representative of a typical nursing home distribution (mostly female). Treatment duration was of particular concern in that many of the studies did not address adverse outcomes that

might be more apparent with longer periods of therapy. The literature cites many potential complications associated with MA such as thrombus formation, fluid retention, increase fat deposition, osteoporosis, impaired glucose regulation and death [33]. To date, no longitudinal studies have been conducted to look at these issues. Ironically, many literature reviews advocate the use of MA as a possible adjunctive treatment for unintentional weight loss in long term care residents [16, 34,35] Other authors do not advocate the use of MA and recommend additional studies in this area [5, 17, 21, 24]. The findings of Bodenner et al.[33], in the most recently published study to date, strongly suggest that MA not only lacks efficacy in the long term care population but may increase mortality. Evans [24] noted that with the use of MA, fat gain is the principle component in the increase in body weight, thus MA is not effective in restoring lean muscle mass associated with nutritional syndromes and unintentional weight loss in the older adults. Perhaps one of the most significant concerns is the risk of thromboembolism (deep vein thrombus or pulmonary embolus) with the use of MA. Residents of long term care who are less mobile in general and more prone to mild dehydration, may be at greater risk for these complications. For the clinician in the long term care setting, a careful evaluation of risk benefit ratio must be considered and based on the evidence to date; MA is not an ideal pharmacotherapeutic agent for treating unintentional weight loss in this population. Based on the strength of the evidence available, none of the appetite stimulants mentioned in this review are recommended for treating unintentional weight loss in this population. The clinician dealing with this type of issue ideally should consider a comprehensive review of all contributing factors associated with unintentional weight loss and rule out any reversible causes. Periodic monitoring of weights, protein stores, labs and functional status should be included as part of a comprehensive plan of care. Consultation with a dietician and modification of diet and the addition of nutritional supplements should also be considered as first line treatment. The use of appetite stimulants should be carefully considered as a last resort, if at all [8].

ACKNOWLEDGEMENT

The author would like to thank Dr. Susan D. Ruppert for her assistance in the revision of this manuscript.

Figure 1

Table 1 Appetite Stimulants in Long Term Care

Author	Purpose/Type of study	Sample/Population	Results/Recommendations	Limitations
Castle, S., Nguyen, C., Joagji, A., Coyne, B., Houston, C., Chan, A., et al. (1996)	Pilot study to determine the effect of Megace (megestrol acetate) on nursing home (NH) patients with weight loss.	Study involved 4 male nursing home residents with weight loss of > 10% of their body weight treated with 400 mg Megace daily for 6 weeks.	Only one subject completed the study, he gained weight (0.4 kg and 1.9 kg) and two remained unchanged.	Sample size too small for statistical analysis and too small to draw any conclusions. Length of study too short to achieve any benefits.
Volker, L., Shih, M., Morris, J., McLaughlin, J., & Volker, M. (1997)	Placebo-controlled crossover design to investigate the effects of dronabinol on dementia patients.	Study involved 18 patients with Alzheimer's disease exhibiting food refusal.	Eleven of the 18 completed the study; body weight increased with dronabinol (p<0.006). Disturbed behavior decreased during treatment as well but was not significant.	Difficult to draw substantial conclusions due to small sample size. A decrease in disturbed behavior might be a contributing factor in weight gain.
Jackson, M.K. (1999)	A non-randomized clinical trial to assess the effects of Megace on malnourished NH patients.	Study involved 27 NH residents with malnutrition, treated with 1200 mg daily dose of Megace.	Study weight increased in 74% of the treated subjects.	Small sample size, non-randomized, control of other factors not discussed.
Thomas, D.R., Ashmet, W., Morley, J.E., & Evans, W.J. (2000)	Clinical Practice Guidelines for Nutritional Management in LTC-clinical practice guideline.	Long term residents suffering from involuntary weight loss.	Orogenic drugs should be considered to reverse anorexia.	Expert consensus was used to assess the quality of the evidence, no rating scheme for the quality/strength was used.
Yeh, S.S., Wu, S.Y., Levine, D.M., Parker, T.S., Olson, J.S., Stevens, M.R., & Schuster, M.W. (2000)	Prospective double blind placebo controlled trial using Megace to examine the correlation between appetite, weight, nutritional status, sense of well being and cytokine levels.	Sample of 69 residents in a VA nursing home older than 65 (only 3 females) with >5% weight loss in the prior 3 months or > 20% loss of BW treated with Megace 800 mg or placebo daily for 12 weeks.	In the MA arm of the trial, appetite improved (p<0.004), enjoyment improved (p<0.025), and sense of well being improved (p<0.045). No significant differences (p> 0.2) in nutritional markers (albumin, prealbumin). Negative correlation between cytokine levels and appetite, prealbumin and albumin but not statistically significant.	Sample size was small but demonstrates need for additional studies to further investigate the relationship between MA and cytokine levels, appetite, weight gain, depression and nutritional markers.
Yeh, S.S., Wu, S.Y., Lee, T.P., Olson, J.S., Stevens, M.R., Olson, T., Pincall, R.J., et al. (2000)	Prospective double blind placebo controlled trial to investigate the effects of Megace on weight, appetite change, sense of well being, enjoyment of life, change in depression, nutrition parameters, body composition and adverse effects.	Sample of 69 residents in a VA nursing home older than 65 (only 3 females) with >5% weight loss in the prior 3 months or > 20% loss of BW treated with Megace 800 mg or placebo daily for 12 weeks (same population as in prior study).	No significant difference in weight gain between the MA and placebo groups in terms of weight gain at 12 weeks (P=2) but significant after a follow up of 26 weeks (P=0.03) with an average gain of 1.82 kg in the MA group. Significant difference between the groups at 12 weeks in terms of appetite, enjoyment and sense of well being (see 2 values in previous citation). No difference in depression score.	Same sample which is small and not generalizable to a larger heterogeneous NH population as in other studies in the LTC population. Further investigations using a larger more heterogeneous NH population over a longer study period.
Yeh, S.S., Wu, S.Y., Levine, D.M., Parker, T.S., Olson, J.S., Stevens, M.R., et al. (2001)	Prospective double blind placebo controlled trial to investigate the correlation between cytokine levels and body weight after treatment with Megace in geriatric patients.	Sample of 69 residents in a VA nursing home older than 65 (only 3 females) with >5% weight loss in the prior 3 months or > 20% loss of BW treated with Megace 800 mg or placebo daily for 12 weeks (same population as in prior study).	Decrease in cytokine levels (IL-6, TNF- α , IL-1, IL-2, IL-8) after treatment with MA as compared to the control group but was not statistically significant.	See comments in previous section.
Huffman, G.B. (2002)	Evaluation and treatment of unintentional weight loss in the elderly. ROL.	Literature review of strategies for evaluation and treatment of weight loss in the NH population.	Comprehensive assessment should be performed to include history, physical, and diagnosis. Treatment should be directed at underlying causes. Several drugs have been used (Megestrol acetate, dronabinol, mirtazapine, nandronolone, megestrolamide, and Phentermine) but few have been studied for use in NH population.	Need for further investigation of orogenesis for specific use in the elderly and in the LTC population. Authors' recommendations are based on one study specific to the NH population.
Morley, J.E. (2002)	Orogenics and anabolic agents. ROL.	Literature review with a focus on agents used to stimulate appetite in older adults.	Megace, dronabinol, osanobronolone and experimental drugs are discussed. Most studies specific to Megace and dronabinol have included cancer and AIDS patients. Only one study using Megace in NH patients was reported.	Use of appetite stimulants in the NH population has not been well studied, is an area in great need of further research.
Sullivan, D.H., Morley, J.E., Johnson, L.E., Barber, A., Olson, J.S., Stevens, M.R. et al. (2002)	Prospective observational study to determine which health or nutrition indicators correlated with weight gain or improvement in appetite and whether weight loss during the study period of 6 months correlated with higher mortality.	1300 patients from 98 long term care facilities were enrolled based on specific inclusion criteria of being at nutritional risk. Appetite improvement, weight gain and mortality were primary outcome measures. Nutritional regimens assessed to include the use of orogenic agents.	Younger age was the strongest correlate of appetite improvement. The odds of gaining weight were negatively correlated with BMI, age, and feeding dependency. 16.0% of patients gained weight >5% compared to 10.7% who did not (p<0.02). A weight loss during the 6 month study was associated with a two fold increase in the likelihood of dying (RR=1.95, 95% CI 1.43-2.66).	Sample size is a strength of the study but here are some confounding variables. Compelling evidence that appetite stimulants increase the likelihood of weight gain, however, the agents were not assessed individually but rather as a group. Replication of the study with separate analyses of each agent is worth pursuing.
Karic, E., Philpot, C., & Morley, J.E. (2002)	Treatment of malnutrition with megestrol acetate. ROL and retrospective study.	Review of megestrol acetate in various populations including AIDS, cancer, dialysis, and other adults. Retrospective review of 12 patients in two long term care facilities treated with megestrol acetate for malnutrition.	Only four studies specific to NH patients were noted with improvements in weight and other nutritional parameters. The authors noted in their review in patients taking 800 mg daily that food intake, BMI, albumin, prealbumin, hemoglobin, white cell count, and Total Lymphocyte TLCL increased with significance of p<0.05.	Studies to this date on the use of Megace suggest benefits, however, no other nutritional parameters and the sample sizes have been consistently small.
Yeh, S.S., Hofer, A., Chiao, C., Levine, D., Parker, T.S., & Schuster, M.W. (2004)	A randomized, double blind placebo controlled clinical trial to evaluate the effect of proinflammatory cytokines, their receptors and nutritional status at baseline and after 12 weeks of treatment with MA upon survival.	Sample of 69 residents in a VA nursing home older than 65 (only 3 females) with >5% weight loss in the prior 3 months or > 20% loss of BW treated with Megace 800 mg or placebo daily for 12 weeks (same population as in prior study).	No significant difference in survival between MA and placebo groups (p=0.3). Elevated cytokines and neutrophil counts were associated with elevated mortality whereas initial and final prealbumin, albumin, and final weight gain were associated with decreased death.	Sample has been the subject of other studies and therefore multiple published studies. In this study, cytokines and protein markers as well as weight gain may be independent risk factors predicting survival in older adults.
Simmons, S.F., Hiner, K.A., & Osterweil, D. (2004)	Prospective pilot study to evaluate the effect of megestrol acetate on oral food and fluid intake in NH residents.	Sample of 17 from four nursing homes (recruited from a larger study on nutritional care quality) treated with a daily dose of 400 mg of Megace for 63 days.	MA had a significant effect on oral food and fluid intake under an optimal meal time feeding assistance condition but not when administered under usual NH feeding conditions. I	Limited by small sample size and when administered under usual NH feeding conditions. I
Aoyama, L., Watanabe, M., & Rubenstein, D.B. (2006)	Review of behavioral measures, nutritional supplements and appetite stimulants in LTC. ROL.	Authors reviewed etiology and interventions related to weight loss among NH residents.	Limited evidence to support the use of cyproheptadine, mirtazapine and antipsychotics in NH residents with weight loss. Megace has been studied but appears to be effective for only a subset of NH residents. Adverse effects include DVT, fluid retention, and diarrhea.	Need for additional clinical trials to investigate the use of appetite stimulants and specifically to evaluate the risk/benefits associated with the use of MA.
Reuben, D.B., Hirsch, S.H., Zhou, H., & Greenstein, G.A. (2006)	A phase II randomized clinical trial To investigate the effects of megestrol acetate on elderly patients post hospitalization.	Sample included 43 older adults recently discharged from an acute care hospital (called elderly at home, treated with placebo, 200 mg, 400 mg or 800 mg daily for 9 weeks.	MA at doses of 400 mg and 800mg increased the prealbumin levels at 30 days (p= 0.00 and p= 0.04, respectively) and those in the 400 mg group demonstrated improvement at 63 days as well (p=0.02). No statistically significant effect on weight gain, functional status, or QOL.	Did not focus on NH residents and so the results are difficult to generalize to NH residents. Implications for the improvement of nutritional markers with the use of MA in older adults. The sample was small and the length of the study was limited to 9 weeks without subsequent follow-up.
Thomas, D. (2006)	Guidelines for the use of orogenic drugs in long term care. ROL and recommendations for practice.	Author reviews key concepts and describes the use of agents including megestrol acetate, dronabinol, corticosteroids and cyproheptadine.	Of the agents discussed, only Megace and dronabinol have been studied specifically in the LTC population with improvement in appetite and weight gain in MA and weight gain in dronabinol.	MA and dronabinol appear to have some promise for increased weight gain in NH residents, but findings are based on a limited number of studies.
Wilson, M.M., Philpot, C., & Morley, J.E. (2006)	Retrospective, observational pilot study to the use of dronabinol as an appetite stimulant in long term care.	Sample of 28 subjects (22F, 6M) in five facilities being treated with dronabinol as an appetite stimulant for a 12 week period.	Fifteen subjects gained weight and seven lost weight. Those who lost weight were likely to be younger. Overall, dronabinol caused a small increase in weight, but was not statistically significant. No adverse effects were reported.	No randomization or control, small sample size. Results do not suggest dronabinol is effective in increasing weight in the population. Authors also note that persistent cognitive dysfunction with dronabinol has been noted in animal studies.
Bodemer, D., Spencer, T., Riggs, A.T., Redman, C., Shank, B., & Amegha, T. (2007)	Case control cohort study to investigate the effects of megestrol acetate on weight gain and mortality in the LTC population.	17328 residents admitted to a NH between January 1, 2000 and December 31, 2003 with 5% loss of body weight in 3 months or 10% who received MA were matched 1:2 with residents that were non MA treated (1100 with MA vs. 14110 non MA treated).	Median survival of MA treated patients (23.9 months, 95% CI 27.8-35.5) was significantly less than in non MA treated patients (21.2 months, 95% CI 27.8-35.5) with p<0.001. Median weight and median of weight differences were unchanged after 6 months of treatment in MA versus non MA treated residents.	Randomized prospective studies of the use of MA in this population are needed to fully evaluate morbidity and mortality associated with the study. Patients with HIV and cancer were also included which could be confounding factors.
Padala, K.P., Yellier, B.K., & Potter, J.F. (2007)	Weight loss treatment in LTC. ROL.	Authors reviewed the use of dietary and environmental changes, nutritional supplements, flavor enhancers and appetite stimulants in NH residents.	Nutritional supplements are beneficial in the treatment of weight loss, but there are limited studies on the use of appetite stimulants specifically in the LTC setting.	More studies examining the use of orogenics in LTC are needed.
Morley, J.E. (2007)	Review of therapeutic approaches to weight loss in older adults. ROL.	Author describes leading causes of weight loss (attributable to factors such as cachexia, sarcopenia, anorexia, and dehydration) with strategies for each condition.	Dronabinol, megestrol acetate, anorectic/antiemetic agents and anabolic steroids and testosterone are recommended as strategies depending upon the etiology.	No specific recommendation for how or when to administer agents nor is there any discussion of doses or adverse effects. Good discussion of physiology but limited practical applicability.

References

1. Blaum, CC, Fries, EB, Fiatorone, MA. Factors associated with low body mass index and weight loss in nursing home residents. *J Gerontol A Biol Med Sci* 50.3 (May 1 1995): M162-168.
2. Yeh, S, Schuster, MW. Geriatric cachexia: the role of cytokines. *Am J Clin Nutr* 70 (1999): 183-97.
3. Centers for Disease Control and Prevention. Nursing Home Care. National Nursing Home Survey. 2004. CDC/National Center for Health Statistics. April 5, 2010 <http://www.cdc.gov/nchs/fastats/nursingh.htm>.
4. Labossiere, R, Bernard, M. Nutritional considerations in institutionalized elders. *Curr Opin Clin Nutr Metab Care* 11 (2008): 1-6.
5. Padala, K P, et al. Weight loss treatment in long term care: are outcomes improved with oral supplements and appetite stimulants? *J Nutr Elderly* 26.(3/4) (2007): 1-20.
6. Schiffman, S S, Graham, BG. Taste and smell perception affect appetite and immunity in the elderly. *Eur J Clin Nutr* 54, suppl3 (June 1 2000): S54-63.
7. Morley, JE, Thomas, DR. Anorexia and aging: pathophysiology. *Nutr* 15 (1999): 499-503.
8. Huffman, GB. Evaluating and treating unintentional weight loss in the eElderly. *Am Fam Phys* 65.4 (February 1 2002): 640-50.
9. Fermia, RA, Goyette, RF. The science of megestrol acetate delivery: potential to improve outcomes in cachexia." *BioDrugs* 19.3 (2005): 179-87.
10. Fox, CB, et al. Megestrol acetate and mirtazepine for the treatment of unplanned weight loss in the elderly. *Pharmacother* 29.4 (2009): 383-97.
11. Yeh, S, et al. Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double blind, placebo controlled study. *J Am Geriatr Soc* 48 (2000): 485-92.
12. Howland, R H. Understanding the clinical profile of a drug on the basis of its pharmacology. *J Psychosoc Nurs* 46.12 (2008): 19-23.
13. Nelson, JC, et al. Mirtazepine nursing home study group, mirtazepine orally disintegrating tablets in depressed nursing home residents. *Int J Geriatr Psychiatr* 9 (September 1 2006): 898-991.
14. Goldberg, R J. Weight change in depressed nursing home residents on mirtazepine. *J Am Geriatr Soc* 50.8 (August 1 2002): 1461.
15. Mihara, IQ, et al. The impact of mirtazepine compared with non TCA antidepressants on weight change in facility residents." *Consult Pharm* 20.3 (March 1 2005): 217-23.
16. Morley, JE. Orixigenic and anabolic agents. *Clin Geriatr Med* 18 (2002): 853-66.
17. Golden, AG, et al. University of Miami division of clinical pharmacology rounds: medications used to treat anorexia in the frail elderly. *Am J Ther* 10 (2003): 292-98.
18. Demling, R, DeSanti, L. Closure of the nonhealing wound corresponds with correction of weight loss using the anabolic agent oxandrolone. *Ostomy Wound Manag* 44 (1998): 58-62.
19. Yeh, SS, et al. M012 study group: reversal of COPD associated weight loss using the anabolic steroid oxandrolone." *Chest* 122.2 (2002): 421-28.
20. Amar, MH. Cannabinoids in medicine; a review of their therapeutic potential." *J Ethnopharmacol* 105 (2006): 1-25.
21. Aoyama, L, et al. Is weight loss in the nursing home reversible? *J Am Medl Dir Assoc* August 1 2005: 250-56.
22. Volicer, L, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. *Inter J Geriatr Psych* 12 (1997): 913-19.
23. Wilson, MG, et al. Anorexia of aging in long term care: is dronabinol an effective appetite stimulant?: a pilot study. *J Nutr, Health Aging* 11.2 (January 1 2006): 195-98.
24. Evans, W. Megestrol acetate for weight gain should be carefully considered. *J Clin Endocrin Metab* 92.2 (2007): 420-21.
25. Wermers, RA, et al. Osteoporosis associated with megestrol acetate. *Mayo Clin Proc* 79.12 (December 1 2004): 1557-61.
26. Castle, SC, et al. Megestrol acetate suspension therapy in the treatment of geriatric anorexia/cachexia in nursing home patients. *J Am Geriatr Soc* 43.7 (July 1 1995): 167-72.
27. Karcic, E., Philpot, C, Morley, JE. Treating malnutrition with megestrol acetate: literature review and review of our experiences *J Nutr* 6.3 (2002): 191-200.
28. Sullivan, DH, et al. The GAIN registry: the impact of appetite and weight on mortality in a long term care population. *J Nutr Health Aging* 65.4 (2002): 275-81.
29. Yeh, S, et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels, nutritional status and appetite in geriatric patients with wasting syndrome. *J Nutr Health Aging* 4.2 (2000): 246-50.
30. Yeh, SS, et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. *J Gerontol* 56A.1 (2001): M48-54.
31. Yeh, SS, et al. Risk factors relating blood markers of inflammation and nutritional status to survival in cachectic geriatric patients in a randomized clinical trial. *J Am Geriatr Soc* 52 (2004): 1708-12.
32. Simmons, SF, et al. The effect of megestrol acetate on oral food and fluid intake in nursing home residents: a pilot study. *J Am Medl Dir Assoc* 6.3 (June 1 2005): S5-11.
33. Bodenner, D, et al. A retrospective study of the association between megestrol acetate administration and mortality among nursing home residents with clinically significant weight loss. *Am J Geriatr Pharmacother* 5.2 (2007): 137-46.
34. Thomas, DR. Guidelines for the use of orixigenic drugs in long term care. *Nutr Clin Pract* 21 (2006): 82-87.
35. Morley, JE. Weight loss in older persons: new therapeutic approaches. *Curr Pharml De* 13 (2007): 3637-47.

Author Information

Dianne M. Rudolph, MSN, RN, GNP-BC, CWOCN

Doctor of Nursing Practice Candidate, School of Nursing, The University of Texas Health Science Center at Houston